Gilead Sciences, Inc. Acquires Arcellx, Inc.

Gilead Sciences, Inc. has entered into a Merger Agreement to acquire Arcellx, Inc. for $115.00 per share in cash, plus a contingent value right of $5.00 per share. This acquisition will be completed through a tender offer, followed by a merger. Gilead has been increasing its stake in Arcellx, with its latest filing indicating an 11.5% ownership. The transaction is expected to be funded by Gilead's existing cash reserves. This move is part of Gilead's strategy to enhance its oncology pipeline through the acquisition of Arcellx's cell therapy technology. The deal is subject to customary closing conditions, including regulatory approvals.